Alkermes (ALKS) Cash from Investing Activities Growth (3y) (2013 - 2026)
Alkermes (ALKS) Cash from Investing Activities Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -26.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.41% |
| Mar 31, 2026 | -212.48% |
| Dec 31, 2025 | 126.50% |
| Sep 30, 2025 | -40.22% |
| Jun 30, 2025 | 10.34% |
| Mar 31, 2025 | 29.07% |
| Dec 31, 2024 | -165.43% |
| Sep 30, 2024 | -51.08% |
| Jun 30, 2024 | 135.36% |
| Mar 31, 2024 | -1.92% |
| Dec 31, 2023 | 15.76% |
| Sep 30, 2023 | -143.90% |
| Jun 30, 2023 | 103.45% |
| Mar 31, 2023 | 60.89% |
| Dec 31, 2022 | 31.49% |
| Sep 30, 2022 | -34.45% |
| Jun 30, 2022 | -77.47% |
| Mar 31, 2022 | 2.14% |
| Dec 31, 2021 | 54.36% |
| Sep 30, 2021 | -47.55% |